Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 27, 2018. The report serves as a transaction notification regarding the administration of Long-Term Incentives. In May 2018, the Company changed suppliers for this administration, necessitating the transfer of Ordinary Shares and American Depositary Shares (ADS) held by Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) from the previous administrator to the new one.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document strictly details administrative share transfers.
| Transaction Date | Instrument Type | Price | Total Volume Transferred |
|---|---|---|---|
| 2018-07-26 | Ordinary Shares | £0.00 | 679,677.116 |
| 2018-07-26 | American Depositary Shares (ADS) | $0.00 | 222,784.525 |
Material Changes
There were no material changes to the Company's financial position or beneficial ownership. The reported transactions represent a transfer of shares between nominee accounts solely to effectuate the change in the Long-Term Incentives administrator. The filing explicitly states there was "No change in beneficial ownership" for any of the transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions were conducted off-market at a price of zero, reflecting their administrative nature rather than a market sale or purchase.
Investor Verification Points
- Verify that the share transfers were purely administrative and did not alter the beneficial ownership of the listed executives.
- Confirm the total volume of Ordinary Shares (approx. 679,677) and ADS (approx. 222,785) moved to the new administrator.
- Note that this filing does not contain financial results; refer to the Company's Form 20-F or interim reports for financial performance data.